CareDx, Inc.
CDNA Nasdaq· Services-Medical Laboratories
Last close · Oct 27, 2026
$70.53
KIRA · Stoqly’s AI analyst, in plain words
- CareDx, Inc. had $380M of revenue in fiscal 2025, up 13.8% on the year before. Over five years, revenue changed +14.6% a year on average.
- Its operating margin was −8.1%, down 20.3 pts: of every 100 in sales, about −8 is left after running the business.
- CareDx, Inc. lost $21.4M in fiscal 2025.
- CareDx, Inc. returned $87.8M to shareholders in fiscal 2025. The diluted share count fell 5.9%.
Market cap
$3.8B
P/E
34.1x
Revenue
$380M
Net income
−$21.4M
Free cash flow
—
Operating margin
−8.1%
CareDx, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+13.8%
Yes. Sales grew 13.8% last year.
Does it make a profit?
−5.6%
No. It lost money last year.
How healthy are the accounts?
4 / 7
Mixed. It passes 4 of 7 health tests.
How is the share priced?
34.1x
One share costs 34.1 times its yearly profit per share.
What CareDx, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 25, 2026
- Legal name
- CareDx, Inc.
- CIK
- 0001217234
CareDx, Inc. · CDNA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $296M | $322M | $280M | $334M | $380M |
| Revenue growth | 54.2% | 8.6% | −12.9% | 19.1% | 13.8% |
| Operating margin | −10.0% | −24.0% | −72.5% | 12.2% | −8.1% |
| Net income | −$30.7M | −$76.6M | −$190M | $52.5M | −$21.4M |
| Net margin | −10.3% | −23.8% | −67.9% | 15.7% | −5.6% |
| Diluted EPS | −$0.59 | −$1.44 | −$3.54 | $0.93 | −$0.40 |
| Cash | |||||
| Cash from operations | −$19.3M | −$25.2M | −$18.4M | $38.0M | $42.0M |
| Share buybacks | $0.0M | $0.6M | $27.5M | $0.5M | $87.8M |
| Share count change | 12.4% | 2.1% | 0.8% | 5.3% | −5.9% |
| Debt and strength | |||||
| Cash and short-term investments | $348M | $293M | $235M | $261M | $177M |
| Shareholders' equity | $466M | $431M | $261M | $378M | $303M |
| Current ratio | 5.6x | 5.1x | 4.0x | 3.9x | 2.9x |
| Returns and quality | |||||
| Return on equity | −8.2% | −17.1% | −55.0% | 16.4% | −6.3% |
| Return on tangible equity | −8.1% | −21.9% | −108.6% | 17.5% | −9.3% |
| Piotroski F-score | 3 | 2 | 2 | 4 | 4 |
| Altman Z'' | 6.4 | 4.1 | −3.0 | 3.4 | 0.2 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$13.3M
7 insiders
Of sales under plans
76%
$10.1M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
CareDx, Inc. · CDNA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $70.53 a share, the company is worth $3.8B: 34.1 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001217234). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.